Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Consensus Recommendation of "Buy" from Brokerages

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has received an average rating of "Buy" from the six ratings firms that are currently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $34.50.

A number of analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Oppenheimer restated an "outperform" rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. Maxim Group lifted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, September 25th. Piper Sandler began coverage on Capricor Therapeutics in a research note on Monday, October 21st. They issued an "overweight" rating and a $35.00 price target on the stock. Finally, Cantor Fitzgerald raised their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, November 14th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC increased its stake in shares of Capricor Therapeutics by 74.8% in the fourth quarter. SG Americas Securities LLC now owns 15,317 shares of the biotechnology company's stock worth $211,000 after purchasing an additional 6,552 shares in the last quarter. Magnus Financial Group LLC purchased a new position in shares of Capricor Therapeutics during the 4th quarter valued at $276,000. Krilogy Financial LLC bought a new position in Capricor Therapeutics in the 4th quarter worth $287,000. JPMorgan Chase & Co. increased its stake in Capricor Therapeutics by 419.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock worth $855,000 after buying an additional 45,381 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Capricor Therapeutics during the third quarter valued at about $458,000. Institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Price Performance

CAPR stock traded up $0.20 during midday trading on Monday, hitting $13.70. The stock had a trading volume of 688,914 shares, compared to its average volume of 1,075,567. The business has a 50-day moving average of $15.34 and a two-hundred day moving average of $11.66. The firm has a market cap of $622.94 million, a price-to-earnings ratio of -12.92 and a beta of 4.08. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.